OBJECTIVES: The purpose of this study was to determine the prognostic value of N-terminal B-type natriuretic peptide (NT-proBNP) in two independent samples of patients presenting with acute coronary syndromes (ACS) and normal troponin T (TnT) values. BACKGROUND: Recently assessment of NT-proBNP has been studied in patients with ACS. However, the clinical relevance in patients who present without troponin elevation is unclear. METHODS: We included 2,614 patients from two independent registries, one serving as a derivation cohort comprising patients with evident ACS (Bad Nauheim ACS registry, n = 1,131) and the other serving as a validation cohort including chest pain patients (PACS [Prognosis in Acute Coronary Syndromes] registry, n = 1,483). NT-proBNP and TnT were measured upon admission. Clinical outcome has been assessed over a 6-month period. RESULTS: In both cohorts, the mortality rate was significantly lower among TnT negative patients: 3.8% versus 8.2% (p = 0.009) in the Bad Nauheim ACS registry, and 2.8% versus 8.6% (p = 0.009) in the PACS registry. Among TnT negative patients, receiver-operating characteristics curve analysis yielded an optimal cutoff value of 474 pg/ml for NT-proBNP that was able to discriminate patients at higher risk in the Bad Nauheim ACS and PACS registries (mortality rate 12.3% vs. 1.3%, p < 0.001 and 8.5% vs. 1.5%, p < 0.001, respectively). By Kaplan-Meier analysis, patients with NT-proBNP values over 474 pg/ml were at higher risk for death in the Bad Nauheim ACS registry (log-rank 19.01, p < 0.001, adjusted hazard ratio [HR] 9.56 [95% confidence interval (CI) 2.42 to 37.7], p = 0.001) and in the PACS registry (log-rank 23.16, p < 0.001, adjusted HR 5.02 [95% CI 2.04 to 12.33], p < 0.001). CONCLUSIONS: Among patients with suspected ACS considered to be at low risk because of normal troponin values, NT-proBNP above 474 pg/ml is able to discriminate individuals at higher risk. Because of its incremental prognostic value, NT-proBNP assessment should be considered in clinical routine for risk stratification of patients with normal troponin.
OBJECTIVES: The purpose of this study was to determine the prognostic value of N-terminal B-type natriuretic peptide (NT-proBNP) in two independent samples of patients presenting with acute coronary syndromes (ACS) and normal troponin T (TnT) values. BACKGROUND: Recently assessment of NT-proBNP has been studied in patients with ACS. However, the clinical relevance in patients who present without troponin elevation is unclear. METHODS: We included 2,614 patients from two independent registries, one serving as a derivation cohort comprising patients with evident ACS (Bad Nauheim ACS registry, n = 1,131) and the other serving as a validation cohort including chest painpatients (PACS [Prognosis in Acute Coronary Syndromes] registry, n = 1,483). NT-proBNP and TnT were measured upon admission. Clinical outcome has been assessed over a 6-month period. RESULTS: In both cohorts, the mortality rate was significantly lower among TnT negative patients: 3.8% versus 8.2% (p = 0.009) in the Bad Nauheim ACS registry, and 2.8% versus 8.6% (p = 0.009) in the PACS registry. Among TnT negative patients, receiver-operating characteristics curve analysis yielded an optimal cutoff value of 474 pg/ml for NT-proBNP that was able to discriminate patients at higher risk in the Bad Nauheim ACS and PACS registries (mortality rate 12.3% vs. 1.3%, p < 0.001 and 8.5% vs. 1.5%, p < 0.001, respectively). By Kaplan-Meier analysis, patients with NT-proBNP values over 474 pg/ml were at higher risk for death in the Bad Nauheim ACS registry (log-rank 19.01, p < 0.001, adjusted hazard ratio [HR] 9.56 [95% confidence interval (CI) 2.42 to 37.7], p = 0.001) and in the PACS registry (log-rank 23.16, p < 0.001, adjusted HR 5.02 [95% CI 2.04 to 12.33], p < 0.001). CONCLUSIONS: Among patients with suspected ACS considered to be at low risk because of normal troponin values, NT-proBNP above 474 pg/ml is able to discriminate individuals at higher risk. Because of its incremental prognostic value, NT-proBNP assessment should be considered in clinical routine for risk stratification of patients with normal troponin.
Authors: Sebastian Szardien; Holger M Nef; Helge Möllmann; Sandra Voss; Christian Troidl; Christoph Liebetrau; Andreas Rolf; Johannes Rixe; Michael Weber; Christian W Hamm Journal: Clin Res Cardiol Date: 2010-09-07 Impact factor: 5.460
Authors: Quynh A Truong; James Bayley; Udo Hoffmann; Fabian Bamberg; Christopher L Schlett; John T Nagurney; Wolfgang Koenig; James L Januzzi Journal: Am Heart J Date: 2012-05-21 Impact factor: 4.749
Authors: Ellen C Keeley; Robert C Schutt; Mark A Marinescu; Marie D Burdick; Robert M Strieter; Borna Mehrad Journal: Transl Res Date: 2016-03-08 Impact factor: 7.012
Authors: O Akgul; H Uyarel; H Pusuroglu; N Isiksacan; S Turen; M Erturk; O Surgit; O Celik; E Oner; A Birant; I F Akturk; N Uslu Journal: Herz Date: 2014-06 Impact factor: 1.443
Authors: Nisha Bansal; Ronit Katz; Lorien Dalrymple; Ian de Boer; Christopher DeFilippi; Bryan Kestenbaum; Meyeon Park; Mark Sarnak; Stephen Seliger; Michael Shlipak Journal: Clin J Am Soc Nephrol Date: 2015-01-20 Impact factor: 8.237
Authors: Jader Cunha de Azevedo; Bruno Cezario Costa Reis; Nathalia Monerat P B Barreto; Diogenes S F Junior; Lais S Prezotti; Victor Rebelo Procaci; Vivian Werneck Octaviano; Andre Volschan; Evandro Tinoco Mesquita; Claudio Tinoco Mesquita Journal: Arq Bras Cardiol Date: 2014-11-18 Impact factor: 2.000